Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
OmniAb Inc. (OABIW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/27/2025: OABIW (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -5.56% | Avg. Invested days 32 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/27/2025 |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta 0.65 | 52 Weeks Range 0.16 - 0.63 | Updated Date 05/17/2025 |
52 Weeks Range 0.16 - 0.63 | Updated Date 05/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -229.11% | Operating Margin (TTM) -453.64% |
Management Effectiveness
Return on Assets (TTM) -13.18% | Return on Equity (TTM) -21.32% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating 92829276 |
Shares Outstanding - | Shares Floating 92829276 | ||
Percent Insiders - | Percent Institutions - |
Upturn AI SWOT
OmniAb Inc.
Company Overview
History and Background
OmniAb, Inc. was formerly Ligand subsidiary Ab Initio Biotherapeutics, Inc.. OmniAb's technology evolved through multiple acquisitions, including Abgenix in 2006 by Amgen, and subsequent technology refinements. The company focuses on antibody discovery using its diverse transgenic animal platforms.
Core Business Areas
- Antibody Discovery Platforms: OmniAb provides access to its OmniRatu00ae, OmniMouseu00ae, OmniFlicu00ae, OmniClicu00ae, and OmniChickenu00ae transgenic animal platforms to discover novel therapeutic antibodies. These platforms offer diverse antibody repertoires and optimized sequences.
- Licensing and Partnering: OmniAb licenses its platforms and collaborates with pharmaceutical and biotechnology companies to develop new antibody-based therapeutics.
- Service Agreements: OmniAb engages in partnerships with pharmaceutical and biotechnology companies for research agreements.
Leadership and Structure
Matt Foehr is the CEO. The organizational structure includes teams focused on platform development, licensing, and partnerships.
Top Products and Market Share
Key Offerings
- OmniRatu00ae: A rat-based platform for generating human therapeutic antibodies. Market share data is not publicly available; it competes with other antibody discovery platforms offered by companies like Harbour BioMed (HBM), and Regeneron (REGN).
- OmniMouseu00ae: A mouse-based platform for generating human therapeutic antibodies. Market share data is not publicly available; it competes with other antibody discovery platforms offered by companies like Harbour BioMed (HBM), and Regeneron (REGN).
- OmniFlicu00ae: A genetically engineered rat to produce fully human common light chain antibodies. Market share data is not publicly available; it competes with other antibody discovery platforms offered by companies like Harbour BioMed (HBM), and Regeneron (REGN).
- OmniClicu00ae: A genetically engineered chicken to produce fully human antibodies with high diversity. Market share data is not publicly available; it competes with other antibody discovery platforms offered by companies like Harbour BioMed (HBM), and Regeneron (REGN).
- OmniChickenu00ae: A genetically engineered chicken to produce fully human antibodies. Market share data is not publicly available; it competes with other antibody discovery platforms offered by companies like Harbour BioMed (HBM), and Regeneron (REGN).
Market Dynamics
Industry Overview
The antibody discovery market is growing, driven by the increasing demand for antibody-based therapeutics for various diseases. It is a competitive market with many players offering various platforms.
Positioning
OmniAb is positioned as a leading provider of transgenic animal platforms for antibody discovery, focusing on diversity and developability of generated antibodies. Its competitive advantage lies in its diverse platform portfolio.
Total Addressable Market (TAM)
The antibody discovery market is estimated to be in the billions of dollars annually. OmniAb is well-positioned to capture a portion of this TAM through licensing and collaborations.
Upturn SWOT Analysis
Strengths
- Diverse transgenic animal platforms
- Proven track record of generating therapeutic antibodies
- Strong IP portfolio
- Established partnerships with pharmaceutical companies
Weaknesses
- Reliance on partnerships for revenue generation
- High dependence on licensing agreements
- Limited control over downstream development
- Smaller size compared to some competitors
Opportunities
- Expanding partnerships with pharmaceutical companies
- Developing new and improved antibody discovery platforms
- Entering new therapeutic areas
- Exploiting AI/ML to improve the antibody discovery process
Threats
- Competition from other antibody discovery platforms
- Technological advancements that could render existing platforms obsolete
- Failure of partnered programs
- Intellectual property disputes
Competitors and Market Share
Key Competitors
- HBM
- REGN
- GILD
Competitive Landscape
OmniAbu2019s competitive advantage lies in its platform diversity and optimized antibody sequences. Disadvantages include its smaller size and reliance on partnerships.
Major Acquisitions
Abgenix
- Year: 2006
- Acquisition Price (USD millions): 2200
- Strategic Rationale: This acquisition formed the foundation for OmniAb's current antibody discovery platform.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is tied to new partnerships and licensing agreements. Historical Growth data is not readily available outside of SEC filings. Use their ticker, OMNIAB (OABI) to find this information or utilize Refinitiv or Bloomberg.
Future Projections: Future growth is dependent on the success of partnered programs and new platform development. Future growth data is not readily available outside of SEC filings. Use their ticker, OMNIAB (OABI) to find this information or utilize Refinitiv or Bloomberg.
Recent Initiatives: Recent initiatives focus on expanding partnerships and improving existing discovery platforms.
Summary
OmniAb is a company with diverse transgenic animal platforms for antibody discovery and several pharmaceutical partnerships for revenue generation. While its platforms have proven successful, the company relies on licensing agreements, and faces competition from larger players in the antibody market. Expansion of partnerships and continuous innovation will be essential for sustained growth. Investors should monitor the success rates of its partnered programs and the evolving competitive landscape.
Peer Comparison
Sources and Disclaimers
Data Sources:
- OmniAb Inc. Investor Relations
- SEC Filings
- Third-party market research reports
- Company press releases
Disclaimers:
The data and analysis provided are for informational purposes only and should not be considered investment advice. Market share data are estimates based on publicly available information and industry reports. Financial data is based on publicly available information as of the current date.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About OmniAb Inc.
Exchange NASDAQ | Headquaters Emeryville, CA, United States | ||
IPO Launch date 2021-09-30 | President, CEO & Director Mr. Matthew W. Foehr | ||
Sector Healthcare | Industry Biotechnology | Full time employees 114 | Website https://www.omniab.com |
Full time employees 114 | Website https://www.omniab.com | ||
OmniAb, Inc., a biotechnology company, licenses discovery research technology to pharmaceutical and biotech companies, and academic institutions to enable the discovery of therapeutics in the United States, Europe, Japan, China, and Canada. The company's technology platform creates and screens diverse antibody repertoires to identify optimal antibodies and other target-binding proteins for partners' drug development efforts. Its OmniAb platform's Biological Intelligence powers the immune systems of its proprietary and engineered transgenic animals to create optimized antibody candidates for human therapeutics. The company's animal-based technologies include OmniRat, OmniChicken, and OmniMouse, which have been genetically modified to generate antibodies with human sequences; OmniFlic, a bispecific rat and OmniClic, a bispecific chicken are designed for discovery of bispecific antibody applications; OmniTaur, which provides cow-inspired antibodies with unique structural characteristics for challenging targets; OmnidAb, an in vivo platform for the discovery of single-domain antibodies based upon a human VH scaffold; and OmniDeep, a suite of in silico, an artificial intelligence (AI) and machine learning tools for therapeutic discovery and optimization through various technologies and capabilities. The company has an agreement with mAbsolve Ltd. for its Fc-silencing platform technology to incorporate the STR technology into antibodies that have been generated using OmniAb's antibody discovery platform. OmniAb, Inc. was founded in 2012 and is headquartered in Emeryville, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.